相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
Jordan Berlin et al.
INVESTIGATIONAL NEW DRUGS (2022)
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Marwan G. Fakih et al.
LANCET ONCOLOGY (2022)
EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer
Ye-Lim Park et al.
ONCOGENE (2022)
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation
Hualin Zhang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy
Shi Shi et al.
BIOORGANIC CHEMISTRY (2022)
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
Lu Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
Tyler S. Beyett et al.
NATURE COMMUNICATIONS (2022)
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC
Thomas W. Gero et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
David E. Heppner et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Kunyu Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras
Xufen Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
Rachel Evans et al.
FRONTIERS IN ONCOLOGY (2022)
Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib
Ulrike Obst-Sander et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer
Ciric To et al.
NATURE CANCER (2022)
Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations
Mengxu Zhu et al.
BMC MOLECULAR AND CELL BIOLOGY (2021)
Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer
Boyeon Kim et al.
CANCER MEDICINE (2021)
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Jing Zhou et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts
Kaibin Zhu et al.
AGING-US (2021)
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
Ilaria Marrocco et al.
EMBO MOLECULAR MEDICINE (2021)
Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems
Xiaojuan Qu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Mohammed A. S. Abourehab et al.
MOLECULES (2021)
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
Francois Gonzalvez et al.
CANCER DISCOVERY (2021)
SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
Luwei Han et al.
FRONTIERS IN PHARMACOLOGY (2021)
Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Han Han et al.
CANCER RESEARCH (2021)
Lazertinib: First Approval
Sohita Dhillon
DRUGS (2021)
Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
Hao Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders
Meng Cheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
EGFR mutation exists in squamous cell lung carcinoma
Alvin Ho-Kwan Cheung et al.
PATHOLOGY (2020)
Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation
Sylwia Jones et al.
SCIENTIFIC REPORTS (2020)
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
Hui Yi Chew et al.
CELL (2020)
Design and synthesis of selective degraders of EGFRL858R/T790M mutant
Xin Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance
Tatiana Shaurova et al.
CANCERS (2020)
Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations
Jaebong Jang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide
Kailun He et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Wen-Qi Cai et al.
FRONTIERS IN ONCOLOGY (2020)
Comprehensive Model for Epidermal Growth Factor Receptor Ligand Binding Involving Conformational States of the Extracellular and the Kinase Domains
Timea Hajdu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
Timothy Price et al.
CANCER BIOLOGY & THERAPY (2020)
xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling
Jinyun Liu et al.
MOLECULAR THERAPY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Discovery of potent small molecule PROTACs targeting mutant EGFR
Hong-Yi Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Mechanisms of EGFR Resistance in Glioblastoma
Peter C. Pan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
Nan Yao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer
Lu Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
Rintu Thomas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
Ciric To et al.
CANCER DISCOVERY (2019)
Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies
Christine M. Parseghian et al.
CLINICAL CANCER RESEARCH (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death
Melkon Iradyan et al.
CANCERS (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
Rintu Thomas et al.
FRONTIERS IN ONCOLOGY (2019)
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors
Dries J. H. De Clercq et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer
Sean P. Kennedy et al.
BREAST CANCER RESEARCH (2019)
Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation
Tomohiro Tanaka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance
Atrish Bagchi et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Emerging functions of the EGFR in cancer
Sara Sigismund et al.
MOLECULAR ONCOLOGY (2018)
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
D. Westover et al.
ANNALS OF ONCOLOGY (2018)
Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors
Ludovic Menard et al.
CANCER RESEARCH (2018)
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer
Azhar Ali et al.
EMBO MOLECULAR MEDICINE (2018)
Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer
Chang Liu et al.
MOLECULAR PHARMACEUTICS (2018)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An et al.
ONCOGENE (2018)
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial
Clara Montagut et al.
JAMA ONCOLOGY (2018)
Understanding the biology of HER3 receptor as a therapeutic target in human cancer
Hui Lyu et al.
Acta Pharmaceutica Sinica B (2018)
Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma
Ji-Jin Yao et al.
CANCER BIOLOGY & THERAPY (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
The Roles of Autophagy in Cancer
Chul Won Yun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem et al.
CELL CHEMICAL BIOLOGY (2018)
EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer
Yasuyuki Okada et al.
MOLECULAR CANCER RESEARCH (2017)
Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer
Sun-ju Byeon et al.
PATHOBIOLOGY (2017)
EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
Amit Joshi et al.
ONCOTARGETS AND THERAPY (2017)
Sortilin limits EGFR signaling by promoting its internalization in lung cancer
Hussein Al-Akhrass et al.
NATURE COMMUNICATIONS (2017)
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Kirstine Jacobsen et al.
NATURE COMMUNICATIONS (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
Elena Ortiz-Zapater et al.
PLOS ONE (2017)
EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines
Debyani Chakravarty et al.
SCIENTIFIC REPORTS (2017)
Hydroxytyrosol, a product from olive oil, reduces colon cancer growth by enhancing epidermal growth factor receptor degradation
Erika Terzuoli et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2016)
Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
Monia Hossam et al.
ARCHIV DER PHARMAZIE (2016)
The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-)
Kenji Tsuchihashi et al.
CANCER RESEARCH (2016)
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
Pedro C. Rodriguez et al.
CLINICAL CANCER RESEARCH (2016)
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Mari Iida et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications
Xiaojun Tan et al.
TRENDS IN CELL BIOLOGY (2016)
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
Jun Wang et al.
ONCOTARGETS AND THERAPY (2016)
Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D
Lu Yang et al.
ONCOTARGET (2016)
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
E. Allen Sickmier et al.
PLOS ONE (2016)
Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis
Wei-Jie Tian et al.
PLOS ONE (2016)
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family
Sean P. Kennedy et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
Emmanuelle Kempf et al.
EUROPEAN RESPIRATORY REVIEW (2016)
The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
Dongxian Jiang et al.
BMC CANCER (2015)
A Kinase-Independent Role for EGF Receptor in Autophagy Initiation
Xiaojun Tan et al.
CELL (2015)
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena et al.
CLINICAL CANCER RESEARCH (2015)
Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies
Andrea Bertotti et al.
CLINICAL CANCER RESEARCH (2015)
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Helle J. Jacobsen et al.
CLINICAL CANCER RESEARCH (2015)
Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway
Yuichi Ohnishi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Dimerization drives EGFR endocytosis through two sets of compatible endocytic codes
Qian Wang et al.
JOURNAL OF CELL SCIENCE (2015)
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
Hsin-Wei Liao et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations
Chang Dong Yeo et al.
LUNG CANCER (2015)
Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC
Ting-Fang Che et al.
ONCOTARGET (2015)
Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation
Lakshmi Reddy Bollu et al.
ONCOTARGET (2015)
Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant
Lu Yang et al.
EBIOMEDICINE (2015)
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
H. J. Lee et al.
BRITISH JOURNAL OF CANCER (2015)
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
Jinjia Chang et al.
ONCOTARGET (2015)
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
Teresa Troiani et al.
CLINICAL CANCER RESEARCH (2014)
TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
Sebastijan Hobor et al.
CLINICAL CANCER RESEARCH (2014)
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Mari Iida et al.
MOLECULAR CANCER (2014)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
Acquired resistance to EGFR-targeted therapies in colorectal cancer
Beth O. Van Emburgh et al.
MOLECULAR ONCOLOGY (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study
K. Govind Babu et al.
ONCOTARGETS AND THERAPY (2014)
Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth
L. Yang et al.
CELL DEATH & DISEASE (2014)
Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks
Sharmistha Chakraborty et al.
NATURE COMMUNICATIONS (2014)
Threshold-controlled ubiquitination of the EGFR directs receptor fate
Sara Sigismund et al.
EMBO JOURNAL (2013)
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
Hui K. Gan et al.
FEBS JOURNAL (2013)
Activity-based kinase profiling of approved tyrosine kinase inhibitors
Daisuke Kitagawa et al.
GENES TO CELLS (2013)
High Expression of Epidermal Growth Factor Receptor Might Predict Poor Survival in Patients with Colon Cancer: A Meta-Analysis
Liu Hong et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2013)
Prolidase Directly Binds and Activates Epidermal Growth Factor Receptor and Stimulates Downstream Signaling
Lu Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Overexpression of EGFR in Head and Neck Squamous Cell Carcinoma Is Associated with Inactivation of SH3GL2 and CDC25A Genes
Guru Prasad Maiti et al.
PLOS ONE (2013)
Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
Mari Iida et al.
NEOPLASIA (2013)
Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
Abdelhamid Beji et al.
CLINICAL CANCER RESEARCH (2012)
A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Matthew G. Fury et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
Keisuke Tabara et al.
PLOS ONE (2012)
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel
Shazad Q. Ashraf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
J. Tanizaki et al.
BRITISH JOURNAL OF CANCER (2011)
INTEGRATING EPIDERMAL GROWTH FACTOR RECEPTOR ASSAY WITH CLINICAL PARAMETERS IMPROVES RISK CLASSIFICATION FOR RELAPSE AND SURVIVAL IN HEAD-AND-NECK SQUAMOUS CELL CARCINOMA
Christine H. Chung et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Targeting the human EGFR family in esophagogastric cancer
Alicia Okines et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
R. L. Rego et al.
BRITISH JOURNAL OF CANCER (2010)
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity
Hu Zhu et al.
CANCER LETTERS (2010)
Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells
Sujin Choi et al.
CANCER LETTERS (2010)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
J. Randolph Hecht et al.
CLINICAL CANCER RESEARCH (2010)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Nuclear trafficking of the epidermal growth factor receptor family membrane proteins
Y-N Wang et al.
ONCOGENE (2010)
Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation
Ariel Talavera et al.
CANCER RESEARCH (2009)
Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
Rama Krishna Kancha et al.
CLINICAL CANCER RESEARCH (2009)
Epidermal Growth Factor Receptor Translocation to the Mitochondria REGULATION AND EFFECT
Michelle L. Demory et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium
Daekee Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Melarkode S. Ramakrishnan et al.
MABS (2009)
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR
Khalid Al-Nedawi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Survival of cancer cells is maintained by EGFR independent of its kinase activity
Zhang Weihua et al.
CANCER CELL (2008)
Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation
Sara Sigismund et al.
DEVELOPMENTAL CELL (2008)
All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells
Rong-Hua Tao et al.
JOURNAL OF CELL SCIENCE (2008)
Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metal loprotease-dependent ectodomain shedding and exosome secretion
Michael P. Sanderson et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
Shiqing Li et al.
STRUCTURE (2008)
Extracellular matrix and HIF-1 signaling: The role of prolidase
Arkadiusz Surazynski et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The epidermal growth factor receptor: from development to tumorigenesis
Maria Sibilia et al.
DIFFERENTIATION (2007)
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling
K. Shtiegman et al.
ONCOGENE (2007)
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
J. Randolph Hecht et al.
CANCER (2007)
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway
Kazuko Sakai et al.
CANCER SCIENCE (2007)
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
Hideharu Kimura et al.
CANCER SCIENCE (2007)
Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery
Gennaro Galizia et al.
WORLD JOURNAL OF SURGERY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations
Marianela Perez-Torres et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib
Floriana Morgillo et al.
CANCER RESEARCH (2006)
Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer
A Psyrri et al.
CLINICAL CANCER RESEARCH (2005)
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma:: an immunohistochemical and chromogenic in situ hybridization study
J Shia et al.
MODERN PATHOLOGY (2005)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Clathrin-independent endocytosis of ubiquitinated cargos
S Sigismund et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
Impact of EGFR expression on colorectal cancer patient prognosis and survival
JP Spano et al.
ANNALS OF ONCOLOGY (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients
R Bei et al.
JOURNAL OF PATHOLOGY (2004)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
TPJ Garrett et al.
MOLECULAR CELL (2003)
Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling
XC Yu et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
分享论文
